Table 3.
First line (N = 36) | Second line (N = 23) | |
---|---|---|
EDPM | 21/36 | 8/23 |
Mitotane (single agent) | 9/36 | 1/23 |
Gemcitabine and capecitabine | – | 1/23 |
Cisplatin and etoposide (+/−mitotane) | – | 2/23 |
Clinical trial | 6/36 | 11/23 |
ACC, adrenal cortical carcinoma; EDPM, mitotane plus etoposide, doxorubicin, and cisplatin